The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Among patients with idiopathic pulmonary fibrosis (IPF), few studies have investigated the clinical impact of anti-fibrotic treatment (AFT) with and without comorbidities. The aim of the study was to determine whether Charlson Comorbidity Index score (CCIS) can predict the efficacy of AFT in patients with IPF. METHODS: We retrospectively assessed data extracted from the medical records of IPF patients who received anti-fibrotic agents between 2009 and 2019. The collected data included age, sex, CCIS, pulmonary function test, high-resolution computed tomography (HRCT) pattern, gender/age/physiology (GAP) score, and 3-year IPF-related events defined as the first acute exacerbation or death within 3 years after starting AFT. RESULTS: We assessed 130 patients (median age, 74 years) who received nintedanib (n = 70) or pirfenidone (n = 60). Median duration of AFT was 425 days. Patients were categorized into high (≥ 3 points) and low (≤ 2 points) CCIS groups. There was no significant difference between the groups in terms of age, sex, duration of AFT, GAP score, or incidence of usual interstitial pneumonia pattern on HRCT except percentage predicted diffusion capacity of lung for carbon monoxide. Also, significant difference was not seen between the groups for 3-year IPF-related events (P = 0.75). Especially, in the low CCIS group but not the high CCIS group, the longer duration of AFT had better disease outcome. CONCLUSION: In the present study, we could not show any relation between CCIS and IPF disease outcomes in patients undergoing AFT, though the longer duration of AFT might be beneficial for IPF outcomes among patients with low CCIS.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study
- Date Crossref
- 19/09/2023
- Éditeur
- Public Library of Science (PLoS)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Yokohama City University Department of Pulmonology pays non établi dans la noticeUniversité ou école supérieure
-
Yokohama Minami Kyosai Hospital pays non établi dans la noticeÉtablissement de santé
-
Kanagawa Cardiovascular and Respiratory Center pays non établi dans la noticeÉtablissement de santé
-
Gunma Chuo Hospital pays non établi dans la noticeÉtablissement de santé
-
Ofuna Chuo Hospital Department of Respiratory Medicine pays non établi dans la noticeÉtablissement de santé
-
Yamato Municipal Hospital Department of Respiratory Medicine pays non établi dans la noticeÉtablissement de santé
-
Fujisawa City Hospital Department of Respiratory Medicine pays non établi dans la noticeÉtablissement de santé
-
Yokohama City University Medical Center pays non établi dans la noticeÉtablissement de santé
-
Yokohama Minami Kyousai Hospital Department of Pulmonology pays non établi dans la noticeÉtablissement de santé
-
Department of Respiratory Medicine pays non établi dans la noticeInstitution
Department of Pulmonology — Yokohama City University, Yokohama Minami Kyosai Hospital et Kanagawa Cardiovascular and Respiratory Center, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.